Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jens Pahl"'
Autor:
Ivica Fucek, Joachim Koch, Thomas Grunwald, Jens Pahl, Christian Breunig, Sonya Ioana Ciulean, Julia Uhlig, Thea Eichenberg, Joe Fischer, Michael Albers, Jan Schmollinger, Christoph Bach, Paul Franz, Anna Dünkel, Stephan Fricke, Ulrike Köhl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2eef947743514f10b49c3e4ac16dee7f
Autor:
Uwe Reusch, Joachim Koch, Sheena Pinto, Susanne Wingert, Jens Pahl, Armin Beez, Sabrina Purr, Arndt Schottelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6e5e4f7765b34750811e4f80882b6f79
Autor:
Joachim Koch, Sheena Pinto, Susanne Wingert, Jens Pahl, Chiara Zambarda, Karolin Guldevall, Christian Breunig, Damien Toullec, Jacopo Fontana, Björn Önfelt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/dde28aa9a42d4f86ae8c60c460702adf
Autor:
Tobias Gutting, Veronika Hauber, Jens Pahl, Kay Klapproth, Wenyue Wu, Ioana Dobrota, Frank Herweck, Juliane Reichling, Laura Helm, Torsten Schroeder, Beifang Li, Philip Weidner, Tianzuo Zhan, Maximilian Eckardt, Johannes Betge, Sebastian Belle, Carsten Sticht, Timo Gaiser, Michael Boutros, Matthias P.A. Ebert, Adelheid Cerwenka, Elke Burgermeister
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor “programmed-cell-death-1” (PD1) and its ligand (PD-L1), because most cases lack the required m
Externí odkaz:
https://doaj.org/article/76d82438b7e2457c9fd5fa68a566c022
Autor:
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer, Erich Rajkovic
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie
Externí odkaz:
https://doaj.org/article/4d63d162888a47209f9f61da3778fcae
Autor:
Felix Funck, Jens Pahl, Lenka Kyjacova, Lukas Freund, Stephanie Oehrl, Galina Gräbe, Silvia Pezer, Jessica C. Hassel, Jonathan Sleeman, Adelheid Cerwenka, Knut Schäkel
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Mononuclear phagocytes and NK cells constitute the first line of innate immune defense. How these cells interact and join forces against cancer is incompletely understood. Here, we observed an early accumulation of slan+ (6-sulfo LacNAc) non-classica
Externí odkaz:
https://doaj.org/article/28064f348eaa4036bfd3cee20027c0c4
Autor:
Georg Gdynia, Sven W. Sauer, Jürgen Kopitz, Dominik Fuchs, Katarina Duglova, Thorsten Ruppert, Matthias Miller, Jens Pahl, Adelheid Cerwenka, Markus Enders, Heimo Mairbäurl, Marcin M. Kamiński, Roland Penzel, Christine Zhang, Jonathan C. Fuller, Rebecca C. Wade, Axel Benner, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister, Hanswalter Zentgraf, Peter Schirmacher, Wilfried Roth
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
HMBG1 is a protein expressed in natural killer cells and is important in immunosurveillance. In this study, the authors show that HMGB1 binds to and inhibits PKM2, resulting in a block in aerobic glycolysis and ultimately cell death.
Externí odkaz:
https://doaj.org/article/6d0982f20a704f85b9b090631aa6eb7d
Publikováno v:
Trends in immunology. 43(11)
Bi-, tri- and multispecific antibodies have enabled the development of targeted cancer immunotherapies redirecting immune effector cells to eliminate malignantly transformed cells. These antibodies allow for simultaneous binding of surface antigens o
Autor:
Chiara Zambarda, Karolin Guldevall, Christian Breunig, Damien Toullec, Jacopo Fontana, Sheena Pinto, Jens Pahl, Susanne Wingert, Joachim Koch, Björn Önfelt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe use of bispecific natural killer (NK) cell engagers has emerged as a successful strategy for immune cell activation and killing of tumor cells through antibody-dependent cellular cytotoxicity (ADCC). Among these, tetravalent, bispecific
Autor:
Martin Treder, Michael Damrat, Torsten Haneke, Stefan Knackmuss, Susanne Wingert, Ute Schniegler-Mattox, Michael Tesar, Thomas Mueller, Michael Kluge, Wolfgang Fischer, Joachim Koch, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Jens Pahl, Erich Rajkovic
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Epidermal growth factor receptor (EGFR)-targeted cancer therapy such as anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors have demonstrated clinical efficacy. However, there remains a medical need addressing limitations of these therapie